To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

This real-world study in China is tracking the safety and effectiveness of sacituzumab govitecan — a targeted chemotherapy drug — for women with HER2-negative metastatic breast cancer (breast cancer that has spread and lacks the HER2 protein). It observes how the drug works in everyday clinical practice. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have metastatic or locally advanced breast cancer confirmed by biopsy - Your breast cancer is HER2-negative - You have already received at least two cycles of sacituzumab govitecan - You have at least one measurable tumor site - You are physically functioning well enough for treatment **You may NOT be eligible if...** - You have not received the required minimum of sacituzumab govitecan treatment - You have another active cancer - Your overall health status is too poor (ECOG score above 2) Talk to your doctor to see if this trial is right for you.